Real-World Data from the Use of Ranolazine in Patients with Stable Angina Pectoris: The RANGER Study.

ABSTRACT: Background: Although ranolazine has been available for years as a second-line treatment to reduce angina attacks in patients with stable angina pectoris, real-world data on the effectiveness, tolerability, and safety of ranolazine are limited. Methods: A non-interventional, prospective study was conducted to assess the effectiveness and safety of ranolazine. Patients eligible for enrolment had a baseline assessment between one and fourteen days after initiating ranolazine for the first time and a follow-up visit three months later. The primary endpoints comprised the weekly frequency of angina attacks, total adverse events, and ranolazine discontinuation rate. The secondary endpoints included the use of short-acting nitrates, changes on the Canadian Cardiovascular Society (CC

SUBMITTER: Olympios C 

PROVIDER: S-EPMC10971156 | biostudies-literature | 2024 Mar

REPOSITORIES: biostudies-literature